Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To describe the safety and tolerability, including laboratory abnormalities following a
single dose of sarilumab or tocilizumab administered subcutaneously (SC) as monotherapy in
Japanese patients with rheumatoid arthritis (RA).
Secondary Objectives:
To describe the laboratory abnormalities (absolute neutrophil count [ANC], platelet counts,
total cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL]
cholesterol, and liver function tests [LFTs]) following a single dose of sarilumab or
tocilizumab administered SC as monotherapy in Japanese patients with RA.
To describe the pharmacokinetics (PK) of sarilumab and tocilizumab.